Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increasing Cervical Cancer Screening Coverage: A randomised, Community-Based Clinical Trial

  • Acera Pérez, Amelia
  • Manresa, J.M.|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Trapero Bertrán, Marta
  • Hidalgo Valls, Pablo Andres
  • Sánchez Sánchez, Norman
  • De Sanjose, Silvia|||0000-0002-5909-676X
Background. Opportunistic cervical cancer screening can lead to suboptimal screening coverage. Coverage could be increased after a personalised invitation to the target population. We present a community randomized intervention study with three strategies aiming to increase screening coverage.Methods. The CRICERVA study is a community-based clinical trial to improve coverage of population based screening in the Cerdanyola SAP area in Barcelona.A total of 32,858 women residing in the study area, aged 30 to 70 years were evaluated. A total of 15,965 women were identified as having no registration of a cervical cytology in the last 3.5 years within the Public Health data base system. Eligible women were assigned to one of four community randomized intervention groups (IGs): (1) (IG1 N = 4197) personalised invitation letter, (2) (IG2 N., Conclusions. The study confirms that using individual contact methods and assigning a fixed screening date notably increases participation in screening. The response to the invitation is strongly dependent on age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer, results from the EPIC Cohort

  • Roura, Esther
  • Travier, Noémie
  • Waterboer, Tim
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Bosch José, Francesc Xavier|||0000-0002-7172-3412
  • Pawlita, Michael
  • Pala, Valeria
  • Weiderpass, Elisabete
  • Margall, Núria|||0000-0001-9370-6931
  • Dillner, Joakim
  • Gram, Inger T.
  • Tjønneland, Anne
  • Munk, Christian
  • Palli, Domenico
  • Khaw, Kay-Tee
  • Overvad, Kim
  • Clavel-Chapelon, Françoise
  • Mesrine, Sylvie
  • Fournier, Agnès
  • Fortner, Renée T.
  • Ose, Jennifer
  • Steffen, Annika
  • Trichopoulou, Antonia
  • Lagiou, Pagona
  • Orfanos, Philippos
  • Masala, Giovanna
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Polidoro, Silvia
  • Mattiello, Amalia
  • Lund, Eiliv
  • Peeters, Petra H.
  • Bueno-de-Mesquita, H. Bas
  • Quirós García, José Ramón
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Navarro Sánchez, Carmen|||0000-0001-8896-7483
  • Barricarte, Aurelio
  • Larrañaga, Nerea
  • Ekström, Johanna
  • Lindquist, David
  • Idahl, Annika
  • Travis, Ruth C.
  • Merritt, Melissa A.
  • Gunter, Marc J.
  • Rinaldi, Sabina
  • Tommasino, Massimo
  • Franceschi, Silvia
  • Riboli, Elio
  • Castellsagué, Xavier|||0000-0002-0802-3595
In addition to HPV, high parity and hormonal contraceptives have been associated with cervical cancer (CC). However, most of the evidence comes from retrospective case-control studies. The aim of this study is to prospectively evaluate associations between hormonal factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC). We followed a cohort of 308,036 women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a questionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS cases were reported. In a nested case-control study, the sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivariate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). The cohort analysis showed that number of full-term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS and ICC (HR = 1.6 and HR = 1.8 respectively for ≥15 years versus never use). Ever use of menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%CI: 0.4-0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices (IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all cases and HPV seropositive controls yielded similar results, revealing a significant inverse association with IUD for combined CIN3/CIS and ICC (OR = 0.7). Even though HPV is the necessary cause of CC, our results suggest that several hormonal factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.